Ligand News and Research

RSS

Clinical trial investigates osteoporosis medication for type 1 diabetes

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States and a top research center for diabetes and other life-threatening illnesses, is leading a phase 1/2 clinical trial investigating an osteoporosis medication as a way to improve beta cell health in people with early type 1 diabetes.

19 Mar 2025

Frequently asked questions about BioAFM

Do you have a question about BioAFM? This article will tell you everything you need to know.

From Bruker BioAFM 17 Mar 2025

Novel cyclic peptide antagonist can be a promising therapeutic approach for MASH

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.

14 Mar 2025

What can you do with a BioAFM instrument?

Even more answers to help understand how BioAFM can be used!

From Bruker BioAFM 14 Mar 2025

New treatment option for advanced thymic carcinoma shows promise

Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic carcinoma.

12 Mar 2025

Novel treatment approach shows promise for advanced HPV-negative head and neck cancer

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC).

7 Mar 2025

Study explores gene interactions in Alzheimer's disease across brain regions

Alzheimer's disease (AD), a neurodegenerative disorder marked by amyloid plaque buildup and cognitive decline, remains a challenging condition to understand at the molecular level.

4 Mar 2025

New chemical reaction enables precise functionalization of peptides and proteins

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a novel chemical reaction that enables the precise functionalization of peptides and proteins.

28 Feb 2025

Artificial ligaments could revolutionize ACL surgery and recovery

Anterior cruciate ligament (ACL) injuries are common, especially among athletes. Each year, over 400 000 ACL reconstruction (ACLR) surgeries are carried out globally.

27 Feb 2025

Study uncovers novel immune evasion mechanism used by key bacterium in periodontitis

Researchers have identified a new mechanism by which a key bacterium in periodontitis evades the immune system.

24 Feb 2025

Sweat fails to match blood in tracking inflammation after heart attacks

Researchers found that while sweat biomarkers remain stable, plasma biomarkers show significant inflammatory changes after a heart attack, highlighting the limitations of sweat analysis for tracking recovery.

17 Feb 2025

Targeted polymersomes boost methotrexate efficacy for aggressive choriocarcinoma treatment

Researchers develop targeted polymersomes loaded with methotrexate for the treatment of gestational choriocarcinoma,

11 Feb 2025

Dysregulation of RNA-binding proteins in rheumatoid arthritis and osteoarthritis

Announcing a new publication for Acta Materia Medica journal. Single-cell RNA sequencing (scRNA-seq) data from published datasets were obtained to investigate the expression and dysregulation of RNA-binding proteins (RBPs), which are critical for alternative mRNA splicing and translational control in rheumatoid arthritis (RA).

6 Feb 2025

Optibrium widens access to industry-leading docking method

Optibrium, a leading developer of software and AI solutions for molecular design today announced the introduction of a new PyMOL Graphical User Interface (GUI) for Surflex-Dock, its industry-leading structure-based design method, which is part of the company’s BioPharmics 3D molecular modelling suite.

5 Feb 2025

Microbes in your gut could determine cancer treatment outcomes

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment, with specific bacterial strains enhancing or inhibiting anti-tumor immunity.

4 Feb 2025

Study uncovers distinct blood protein signature in children with Long COVID

Distinct protein profiles linked to inflammation and angiogenesis found in children with Long COVID, paving the way for improved diagnostics and therapies.

28 Jan 2025

Research could lead to better medicines and new tools in synthetic biology

Proteins are life's engines, powering processes like muscle movement, vision, and chemical reactions. Their environments-water, lipid membranes, or other condensed phases-are critical to their function, shaping their structure and interactions.

24 Jan 2025

Enhanced biosensing technology detects molecules at lower concentrations

An unplugged electric instrument may function, but it sounds much better when it is connected to an amplifier.

13 Jan 2025

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025

Breakthrough in chemical synthesis expands possibilities for ketones and esters

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with an alcohol) to be locked treasure chests of possibilities.